Lowe Brockenbrough & Co. Inc. lowered its position in Pfizer, Inc. (NYSE:PFE) by 1.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,428 shares of the biopharmaceutical company’s stock after selling 256 shares during the quarter. Lowe Brockenbrough & Co. Inc.’s holdings in Pfizer were worth $686,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. D. Scott Neal Inc. lifted its position in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new stake in Pfizer in the first quarter valued at approximately $121,000. Cascade Investment Advisors Inc. lifted its position in Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 2,200 shares during the last quarter. Patten Group Inc. lifted its position in Pfizer by 5.1% in the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 252 shares during the last quarter. Finally, Acropolis Investment Management LLC lifted its position in Pfizer by 6.7% in the second quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 352 shares during the last quarter. 69.01% of the stock is owned by institutional investors and hedge funds.
Several analysts have weighed in on the company. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. Berenberg Bank set a $39.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, August 1st. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Tuesday, October 3rd. Cowen and Company set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Monday, August 14th. Finally, Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective for the company. in a research report on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. Pfizer currently has an average rating of “Hold” and a consensus target price of $38.32.
Pfizer, Inc. (NYSE PFE) opened at 35.15 on Tuesday. The company has a market cap of $209.05 billion, a P/E ratio of 25.71 and a beta of 1.00. The firm has a 50-day moving average price of $35.84 and a 200-day moving average price of $33.91. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $36.78.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. During the same period in the previous year, the company posted $0.64 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.64%. Pfizer’s dividend payout ratio (DPR) is 94.12%.
In related news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the transaction, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 464,521 shares of company stock worth $15,813,961. 0.06% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/10/31/lowe-brockenbrough-co-inc-cuts-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.